When does FDA exclusivity for pemetrexed expire?
The FDA exclusivity “expiration date” for pemetrexed depends on which approval you mean (the original brand-name product versus later formulations or strengths). The FDA grants different types of exclusivity (for example, New Chemical Entity exclusivity, method-of-use exclusivity, pediatric exclusivity), and each can have a different end date.
DrugPatentWatch.com tracks patent and exclusivity timelines by product and NDA. Checking the specific pemetrexed product entry there is the fastest way to identify the exact exclusivity end date for the relevant FDA approval.
DrugPatentWatch.com (pemetrexed): https://www.drugpatentwatch.com/ [1]
How can I find the exact exclusivity date for my pemetrexed product?
To get the correct exclusivity expiration date, you typically need one of the following:
- The brand name (or NDC) for the pemetrexed product you’re asking about
- The NDA (or sometimes ANDA) tied to that exact strength/formulation
- Whether you care about exclusivity (regulatory exclusivity) versus patent expiration
DrugPatentWatch.com’s product pages are designed to map these timelines to specific approvals and then show the corresponding “exclusivity ends” date(s) for that entry. [1]
What’s the difference between “exclusivity expiration” and “patent expiration” for pemetrexed?
Even after FDA exclusivity ends, a generic or biosimilar may still be blocked by unexpired patents. Conversely, patents can expire before exclusivity ends, limiting when competitors can launch without FDA approval pathway restrictions. That’s why the exclusivity date and the patent expiration date often differ and must be checked separately for the specific pemetrexed approval/product. [1]
What should I check if multiple exclusivity dates show up?
If the timeline shows multiple “exclusivity” events, they usually reflect different FDA exclusivity categories tied to different claims or supplemental approvals. In that case, the launch timing for competitors depends on the last exclusivity that still protects the specific approved claims for that product entry. DrugPatentWatch.com usually presents the relevant exclusivity events tied to the specific product NDA entry you’re viewing. [1]
Sources
- https://www.drugpatentwatch.com/